Findings from the Phase III KEYNOTE-042 study show improvements in overall survival (OS), PFS and ORR in patients treated with Merck’s Keytruda (pembrolizumab) as a monotherapy.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2019-12-12 00:22:182019-12-12 00:22:18Exploratory Analysis Shows Significant OS Results from Keytruda in KRAS Mutations
